.

Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Citi
QuintilesIMS
Baxter
Cantor Fitzgerald
Queensland Health
Johnson and Johnson
UBS
McKesson
Boehringer Ingelheim
AstraZeneca

Generated: November 24, 2017

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 018569

« Back to Dashboard
NDA 018569 describes FUROSEMIDE, which is a drug marketed by Sun Pharm Inds, Fresenius Kabi Usa, Watson Labs, Abraxis Pharm, Ipca Labs Ltd, Ivax Sub Teva Pharms, Astrazeneca, Dava Pharms Inc, Accord Hlthcare, Marsam Pharms Llc, Warner Chilcott, Smith And Nephew, West-ward Pharms Int, Intl Medication, Emcure Pharms Ltd, Watson Labs Teva, Hospira, Wockhardt, Baxter Hlthcare Corp, Sandoz, Amneal Pharms Co, Sun Pharm Inds Inc, Kalapharm, Wyeth Ayerst, Superpharm, Luitpold, Mylan, Mutual Pharm, Leading Pharma Llc, Igi Labs Inc, and Prinston Inc, and is included in fifty-seven NDAs. It is available from sixty-two suppliers. Additional details are available on the FUROSEMIDE profile page.

The generic ingredient in FUROSEMIDE is furosemide. There are twenty-one drug master file entries for this compound. Sixty-four suppliers are listed for this compound. Additional details are available on the furosemide profile page.

Summary for 018569

Tradename:
1
Applicant:
1
Ingredient:
1
Patents:0
Therapeutic Class:Cardiovascular Agents
Formulation / Manufacturing:see details

Pharmacology for NDA: 018569

Medical Subject Heading (MeSH) Categories for 018569

Suppliers and Packaging for NDA: 018569

Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
FUROSEMIDE
furosemide
TABLET;ORAL 018569 NDA NCS HealthCare of KY, Inc dba Vangard Labs 0615-1571 0615-1571-14 14 TABLET in 1 BLISTER PACK (0615-1571-14)
FUROSEMIDE
furosemide
TABLET;ORAL 018569 NDA NCS HealthCare of KY, Inc dba Vangard Labs 0615-1571 0615-1571-31 31 TABLET in 1 BLISTER PACK (0615-1571-31)

Summary for product number 001

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrength40MG
Approval Date:Approved Prior to Jan 1, 1982TE:ABRLD:No

Summary for product number 002

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrength20MG
Approval Date:Approved Prior to Jan 1, 1982TE:ABRLD:No

Summary for product number 005

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrength80MG
Approval Date:Aug 14, 1984TE:ABRLD:No


Complete Access Available with Subscription
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Chinese Patent Office
Cerilliant
UBS
Healthtrust
Boehringer Ingelheim
McKesson
QuintilesIMS
Argus Health
Johnson and Johnson
US Army

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot